Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GI-5005: Additional Phase IIb data

Additional data from a prospective subgroup of treatment-naïve patients (n=102) in an open-label Phase IIb trial showed that GI-5005 plus pegylated interferon alpha-2a and ribavirin non-significantly increased response

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE